U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Staphylococcus saprophyticus Infection

; .

Author Information and Affiliations

Last Update: June 26, 2023.

Continuing Education Activity

Staphylococcus saprophyticus is a Gram-positive bacterium that is a common cause of uncomplicated urinary tract infections, especially in young sexually active females. It is also responsible for complications including acute pyelonephritis, epididymitis, prostatitis, and urethritis. This activity illustrates the evaluation and management of Staphylococcus saprophyticus infections and describes the role of the interprofessional team in managing those with this condition.


  • Describe the infections caused by S. saprophyticus.
  • Review the pathophysiology of S. saprophyticus infections.
  • Summarize the treatment options for S saprophyticus.
  • Outline the importance of improving care coordination among the interprofessional team in enhancing the delivery of care for those with this condition.
Access free multiple choice questions on this topic.


Staphylococcus saprophyticus is a Gram-positive, coagulase-negative, non-hemolytic coccus that is a common cause of uncomplicated urinary tract infections (UTIs), particularly in young sexually active females. Less commonly, it is responsible for complications including acute pyelonephritis, urethritis, epididymitis, and prostatitis.[1][2]

An acute uncomplicated UTI is characterized by dysuria and frequency in an immunocompetent, non-pregnant adult female and is the most common bacterial infection in women. A complicated infection typically involves a patient that is immunocompromised, elderly, male, pregnant, diabetic, and/or with urologic abnormalities such as indwelling catheters or kidney disease.

S. saprophyticus can be differentiated from another coagulase-negative staphylococcus by its resistance to Novobiocin. Like other uropathogens, S. saprophyticus utilizes urease to produce ammonia. However, unlike many of these organisms, it cannot reduce nitrate.

S. saprophyticus is part of the normal human flora that colonizes the perineum, rectum, urethra, cervix, and gastrointestinal tract. It has also been found that S. saprophyticus is a common gastrointestinal flora in pigs and cows and thus may be transferred to humans through eating these respective foods.


S. saprophyticus is the second most common cause of community-acquired urinary tract infections, after Escherichia coli. In females ages 16 to 25, it causes up to 42% of all infections. Over 40% of all young, sexually active women contain S. saprophyticus as part of their normal genitourinary flora.[3][4][5]

Patients with nosocomial UTIs, the elderly, pregnant patients, and those with urinary catheterization have an increased incidence of S. saprophyticus colonization. Men have a lower incidence of S. saprophyticus infections.

General risk factors for UTIs include the history of recurrent UTIs, female sex, recent sexual intercourse, pregnancy, neurogenic bladder, indwelling catheter, and benign prostatic hypertrophy.[6][7]

S. saprophyticus is also a common culprit involved in polymicrobial UTIs. Polymicrobial infections are more likely to occur in patients that are immunocompromised, elderly, those who have diabetes, have indwelling catheters, HIV, and/or malignancies. Polymicrobial infections are less common in young, healthy, sexually active females.


In the United States, urinary discomfort is a common complaint in patients seeking medical attention. UTIs are one of the top 10 diagnoses made in emergency departments annually. Nearly half of all women will experience a UTI in their lifetime, and between 5% and 20% of non-hospitalized patients, the infection will be due to S. saprophyticus. Despite highly successful treatment rates, up to 60% of all patients will experience a recurrent UTI within one year.


Bacterial colonization of the bladder and ureter epithelium by S. saprophyticus occurs via several different types of adhesins. These include hemagglutinins with autolytic and adhesive properties, as well as surface-associated lipase that forms fimbria-like surface appendages, helping the bacteria to maintain tight adherence to these surfaces.

It is suspected that the high survivability of S. saprophyticus inside the urinary tract is in part due to the adhesins anchored within the cell wall, allowing the organism to effectively adhere and colonize the uroepithelium, together with urease, which contributes to the persistent growth of the infection.

Some strains of S. saprophyticus have the ability to create biofilms, increasing their virulence, especially in patients with catheters. Once biofilms have been produced, antibiotic resistance is exacerbated. In these cases, S. Saprophyticus may be resistant to vancomycin and only effectively treated via linezolid.

History and Physical

The characteristic history of dysuria, urinary frequency, urinary urgency, and suprapubic pain will be common in symptomatic UTI patients. In those patients with pyelonephritis, back or flank pain, nausea, and fever or chills may also be present.

Physical examination may reveal suprapubic tenderness, in 10% to 20% of cases, and should include urine specimen for analysis. However, in most cases of uncomplicated UTI, a physical examination is unremarkable. In complicated cases or pyelonephritis, patients may present with fever, tachycardia, and/or costovertebral angle tenderness.


The diagnosis of S. saprophyticus requires a confirmatory urine culture. A positive culture is indicated by greater than 100,000 colony-forming units per mL, with a sensitivity and specificity of more than 90%.

UTI, in general, may be diagnosed more cost-effectively with a urine dipstick alone. A dipstick that is positive for leukocytes esterase and/or nitrites is the most simplistic method of UTI diagnosis. In cases of negative dipstick results, and high clinical suspicion, a bacterial urine culture should also be obtained.[8][9]

  • An adequate urine sample should be obtained from a mid-stream catch or straight catheterization, which more effectively avoids contamination.

Imaging is not necessary for cases of uncomplicated UTIs. If renal pathology, such as pyelonephritis, is suspected a CT scan is the most sensitive modality for demonstrating complications such as hydronephrosis or renal abscess.

Treatment / Management

Treatment with outpatient antibiotics is indicated in symptomatic or complicated UTIs and pyelonephritis. It is important to take into consideration specific local resistance patterns when choosing appropriate antibiotic coverage.[10]

The antibiotic of choice in uncomplicated S. saprophyticus UTIs is nitrofurantoin 100 mg orally twice daily for five days, or for seven days in complicated cases. Trimethoprim-sulfamethoxazole (TMP-SMX) 160 mg/800 mg by mouth twice daily for three days may be given alternatively in uncomplicated cases.

Symptomatic treatment for pain and nausea should also be addressed.  Acute uncomplicated UTIs are unlikely to cause renal injury. Thus NSAIDs are a preferred analgesic. Pyridium may also be given to alleviate associated dysuria. Ondansetron or promethazine are commonly prescribed antiemetics. Most patients will notice symptomatic relief within 36 hours from antibiotic treatment alone.

Patients who are hemodynamically unstable, have associated kidney injury, abscess formation, or emphysematous pyelonephritis, have failed outpatient treatment, have intractable nausea, vomiting, or pain, are unable to tolerate oral intake, or are unable to comply with medical treatment may require admission.

Differential Diagnosis

Other diagnoses include non-S. saprophyticus UTI or cystitis, urethritis, pyelonephritis, or nephrolithiasis.


The majority of S. saprophyticus infections can be adequately treated with antibiotics. However, if left untreated, they may progress to pyelonephritis. Untreated pyelonephritis may lead to further complications, such as renal insufficiency.

Pearls and Other Issues

It is important to note that the diagnosis of UTI based on the combination of both leukocyte esterase and nitrites, will miss cases caused by S. saprophyticus. Like most other gram-positive uropathogens, S. saprophyticus does not reduce nitrate to nitrite.

S. saprophyticus has resistance to antibiotic regimes commonly prescribed and effective for E. coli induced UTIs, including ampicillin, ceftriaxone, cephalexin, and ciprofloxacin. In cases where UTI symptoms persist following treatment with one of the previously mentioned antibiotics, S. saprophyticus should be highly suspected.

Enhancing Healthcare Team Outcomes

UTIs are usually managed by the primary care provider, nurse practitioner, and internist. however, not all UTIs are due to gram-negative organisms. In some cases, the organism may be S.Saprophyticus, which can only be identified following culture. While culture is not routine in all patients with a UTI, when the patient fails to improve, one must suspect a different organism and send the urine for culture.

Treatment with outpatient antibiotics is indicated in symptomatic or complicated UTIs and pyelonephritis. It is important to take into consideration specific local resistance patterns when choosing appropriate antibiotic coverage.

Patients who are hemodynamically unstable, have associated kidney injury, abscess formation, or emphysematous pyelonephritis, have failed outpatient treatment, have intractable nausea, vomiting, or pain, are unable to tolerate oral intake, or are unable to comply with medical treatment may require admission. These patients may need IV antibiotics and radiological studies to determine the extent of the infection.

When treated promptly, most patients have good outcomes.[11] (Level V)

Review Questions


Argemi X, Hansmann Y, Prola K, Prévost G. Coagulase-Negative Staphylococci Pathogenomics. Int J Mol Sci. 2019 Mar 11;20(5) [PMC free article: PMC6429511] [PubMed: 30862021]
Pinault L, Chabrière E, Raoult D, Fenollar F. Direct Identification of Pathogens in Urine by Use of a Specific Matrix-Assisted Laser Desorption Ionization-Time of Flight Spectrum Database. J Clin Microbiol. 2019 Apr;57(4) [PMC free article: PMC6440795] [PubMed: 30700506]
Natsis NE, Cohen PR. Coagulase-Negative Staphylococcus Skin and Soft Tissue Infections. Am J Clin Dermatol. 2018 Oct;19(5):671-677. [PubMed: 29882122]
Lala V, Leslie SW, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 30, 2023. Acute Cystitis. [PubMed: 29083726]
Hur J, Lee A, Hong J, Jo WY, Cho OH, Kim S, Bae IG. Staphylococcus saprophyticus Bacteremia originating from Urinary Tract Infections: A Case Report and Literature Review. Infect Chemother. 2016 Jun;48(2):136-9. [PMC free article: PMC4945724] [PubMed: 27433385]
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84. [PMC free article: PMC4457377] [PubMed: 25853778]
Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014 Oct;27(4):870-926. [PMC free article: PMC4187637] [PubMed: 25278577]
Stock I. [Nitrofurantoin--clinical relevance in uncomplicated urinary tract infections]. Med Monatsschr Pharm. 2014 Jul;37(7):242-8. [PubMed: 25065160]
Mirone V, Franco M. Clinical aspects of antimicrobial prophylaxis for invasive urological procedures. J Chemother. 2014 Oct;26 Suppl 1:S1-S13. [PubMed: 25245706]
Widerström M, Wiström J, Sjöstedt A, Monsen T. Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus. Eur J Clin Microbiol Infect Dis. 2012 Jan;31(1):7-20. [PubMed: 21533877]
Stuart JI, John MA, Milburn S, Diagre D, Wilson B, Hussain Z. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin. Int J Antimicrob Agents. 2011 Mar;37(3):248-52. [PubMed: 21295951]

Disclosure: Sarah Ehlers declares no relevant financial relationships with ineligible companies.

Disclosure: Stefan Merrill declares no relevant financial relationships with ineligible companies.

Copyright © 2023, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK482367PMID: 29493989


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...